Expert interpretation of adenovirus vector vaccine: single-dose vaccination accelerates the construction of immune barrier

(Fighting New Coronary Pneumonia ) Expert Interpretation of Adenovirus Vector Vaccine: Single-dose vaccination accelerates the construction of immune barrier

At the media communication meeting with experts on the prevention and treatment of new coronary pneumonia and vaccine application held in Beijing the day before yesterday, Yu Xuefeng, chairman of Cansino Biotech Co.

Chinese State Drug Administration conditionally approved the Kangxi Nuo biological stock company restructuring novel coronavirus vaccine (adenovirus type 5 vector) application for registration Kewei Suo office on February 25.

According to public reports, Keweisha uses a single-dose immunization program that can be stored stably at a temperature between 2 and 8 degrees Celsius.

The communication meeting on the same day also revealed that the vaccine's Phase III clinical trial results showed that a single injection can produce effective protection 14 days after vaccination.

Yu Xuefeng said that the vaccine uses a single-dose immunization program, with the aim of expanding the coverage of the vaccine, building a herd immune barrier as soon as possible, and stopping the pandemic as soon as possible.

Looking back on the global new coronavirus vaccine development process for more than a year, this recombinant new coronavirus vaccine (type 5 adenovirus vector) in China entered clinical trials first, but before its marketing registration application was approved, there were already two inactivated new coronavirus vaccines With the conditional approval of the State Food and Drug Administration of China, an inactivated new crown vaccine was approved on February 25 on the same day.

Why is it the first to carry out clinical trials in the world but not the first to be approved for marketing? Yu Xuefeng said that vaccines are conducting global multi-center phase III clinical studies in more than 70 clinical research centers in 5 countries, with strict standards and complicated processes.

Long-term stable storage between 2 and 8 degrees Celsius is a major feature of this vaccine.

At present, the United Kingdom, South Africa, Brazil, Japan and other countries have reported the detection of mutated new coronaviruses, and they have even become the dominant strains in some places.

Yu Xuefeng said that for most of the current strains, the protective effect provided by the new crown vaccine is not much different, even if the key points are changed, which affects the effect of the existing vaccine.

Speaking further about virus mutation, Feng Luzhao, executive vice president of the School of Medicine and Public Health of Peking Union Medical College, pointed out that the key point is whether the mutation occurs at the key point of the virus gene, so as to affect the transmission, pathogenicity, and vaccine effect of the virus.

"General mutations are like'changing clothes' and do not affect my recognition of you.

Speaking of the future coexistence of the new coronavirus with humans, Feng Luzhao believes that the relevant trends and status are still uncertain.

First of all, unlike SARS, which are mostly severely ill patients, there are a large number of asymptomatic infections of the new coronavirus, which also makes it difficult to eradicate the new coronavirus.

Feng Luzhao also said that the possibility of seasonal onset of new crown pneumonia in winter and spring is not ruled out in the future, but the specific "annual epidemic" or "epidemic once every three years and five years" depends on the population's immunity to the new crown virus.